FUNDAMENTALS · Fundamentals · AU Healthcare

Arovella Therapeutics (ALA) Fundamentals 2026 — Revenue Analysis | SniperIQ

Arovella Therapeutics (ALA) is a AU-listed Healthcare company in Biotechnology with a market capitalization of A$77M, trading at A$0.06 on the ASX. This SniperIQ fundamentals page covers Arovella Therapeutics's valuation, profitability (net margin 240.0%), revenue (A

36,000 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapA$77M
Net Margin240.0%
Revenue (FY25)A
36,000

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Arovella Therapeutics's market cap?

Arovella Therapeutics (ALA) has a market capitalization of approximately A$77M, trading at A$0.06 on the ASX. Market cap moves with the live share price.

What is Arovella Therapeutics's P/E ratio?

Arovella Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 4.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Arovella Therapeutics?

Arovella Therapeutics runs a net profit margin of 240.0%, a gross margin of 101.8%, and an operating margin of 481.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Arovella Therapeutics generate?

Arovella Therapeutics reported revenue of A

36,000 for fiscal year 2025, with net income of -A$8M and earnings per share (EPS) of -0.0068. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Arovella Therapeutics pay a dividend?

Arovella Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Arovella Therapeutics financially healthy?

Arovella Therapeutics carries a debt-to-equity ratio of 0.00x and a current ratio of 15.36x, with a market beta of 0.13. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Arovella Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Arovella Therapeutics (ALA) the key facts are: market cap A$77M, revenue A

36,000, 52-week range 0.062-0.125. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Arovella Therapeutics's full fundamentals live

Get Arovella Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Heron Therapeutics (HRTX) fundamentals · NRx Pharmaceuticals (NRXP) fundamentals · Outset Medical (OM) fundamentals · Biomea Fusion (BMEA) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons